Readily isolated bispecific antibodies with native immunoglobulin format

Patent metadata

Field	Value
Publication number	US-9309326-B2
Application number	US-201314034906-A
Country	US
Kind code	B2
Filing date	Sep 24, 2013
Priority date	Jun 26, 2009
Publication date	Apr 12, 2016
Grant date	Apr 12, 2016

Abstract

A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.

First claim

What is claimed is:

1. A method for making an antigen-binding protein, comprising:
(a) culturing a cell containing
(i) a first nucleic acid encoding a first immunoglobulin heavy chain comprising a first variable domain that recognizes a first epitope, wherein the first immunoglobulin heavy chain comprises a first CH3 region of a human IgG selected from IgG1, IgG2, and IgG4, wherein the first CH3 region binds to Protein A;
(ii) a second nucleic acid encoding a second immunoglobulin heavy chain comprising a second variable domain that recognizes a second epitope, wherein the second immunoglobulin heavy chain comprises a second CH3 region of a human IgG selected from IgG1, IgG2, and IgG4, wherein the second CH3 region comprises a modification that reduces or eliminates binding of the second CH3 region to Protein A;
(iii) a third nucleic acid encoding an immunoglobulin light chain that pairs with the first and the second immunoglobulin heavy chain;

under conditions that allow the cell to express the first and the second immunoglobulin heavy chain and the immunoglobulin light chain to generate the antigen-binding protein, wherein the antigen-binding protein is heterodimeric with respect to Protein A binding; and,
(b) isolating the antigen-binding protein from the cell using Protein A.

2. The method of claim 1 , wherein the first and second immunoglobulin heavy chains are human IgG heavy chains.

3. The method of claim 2 , wherein the first and second immunoglobulin heavy chains are each human IgG1 heavy chains.

4. The method of claim 1 , wherein the immunoglobulin light chain is a human immunoglobulin light chain.

5. The method of claim 1 , wherein the modification is selected from the group consisting of (a) 95R, and (b) 95R and 96F in the IMGT exon numbering system, or (a′) 435R, and (b′) 435R and 436F in the EU numbering system.

6. The method of claim 5 , wherein the second CH3 region further comprises one to five modifications selected from the group consisting of 16E, 18M, 44S, 52N, 57M, and 82I in the IMGT numbering system, or 356E, 358M, 384S, 392N, 397M, and 422I in the EU numbering system.

7. The method of claim 1 , wherein the modification does not alter serum half-life of the antigen-binding protein as compared with a corresponding antigen-binding protein that lacks the modification.

8. The method of claim 5 , wherein the second CH3 region of the antigen-binding protein is non-immunogenic or substantially non-immunogenic in a human.

9. The method of claim 1 , wherein the cell is selected from a CHO cell, COS cell, 293 cell, HeLa cell, insect cell, and a retinal cell.

10. The method of claim 9 , wherein the cell is a CHO cell.

11. The method of claim 1 , where the antigen-binding protein is isolated on a solid support comprising Protein A.

12. The method of claim 11 , wherein the solid support comprises a Protein A affinity column and the antigen-binding protein is isolated employing a pH gradient.

13. The method of claim 12 , wherein the pH gradient is a step gradient comprising one or more pH steps between pH 3 and pH 5.

14. The method of claim 13 , wherein the antigen-binding protein elutes at a pH between about 3.9 and about 4.4.

15. The method of claim 14 , wherein the antigen-binding protein elutes at a pH of about 4.2.

16. The method of claim 1 , wherein the first and second nucleic acid are each obtained from a genetically modified mouse.

17. The method of claim 16 , wherein the genetically modified mouse comprises one or more human heavy chain variable region nucleic acid sequences.

18. The method of claim 1 , wherein the first, second and third nucleic acids are introduced into the cell using a vector or a virus carrying the nucleic acids.

19. The method of claim 18 , wherein
(a) the first and second nucleic acid sequences are on the same vector or virus;
(b) the first and third nucleic acid sequences are on the same vector or virus; or
(c) the first, second and third nucleic acid sequences are on the same vector or virus.

Assignees

• Regeneron Pharma

Inventors

• Davis Samuel
• Smith Eric
• Macdonald Douglas
• Olson Kara Louise

Classifications

• C07K2317/31

  multispecific · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K16/06 Primary

  from serum · CPC title

• C07K16/468 Primary

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title